Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Progyny

Under the Radar: Hunting Smart in the Alleyway of Value and Growth

One of the biggest challenges in investing is finding stocks that combine the best of both worlds: the long-term upside of growth and the downside protection of solid fundamentals. That is the space where I like to hunt in the alleyway between value and growth, where stocks trade cheaply not…

Progyny Earns Relative Strength Rating Upgrade

Progyny Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Progyny shows improving technical performance. Will it continue?

Investors Business Daily

Progyny Sees Relative Strength Rating Improve To 72

Progyny Sees Relative Strength Rating Improve To 72

A Relative Strength Rating upgrade for Progyny shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Progyny Sees Its Composite Rating Rise To 96

The IBD SmartSelect Composite Rating for Progyny rose from 92 to 96 Thursday.

Investors Business Daily

Stocks Showing Rising Market Leadership: Progyny Earns 82 RS Rating

Progyny shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 72 to 82.

Investors Business Daily

Progyny Stock Sees RS Rating Improve To 73

A Relative Strength Rating upgrade for Progyny shows improving technical performance. Will it continue?

Investors Business Daily

Progyny Sees RS Rating Rise To 72

Progyny shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Stocks Showing Improving Market Leadership: Progyny Earns 82 RS Rating

Stocks Showing Improving Market Leadership: Progyny Earns 82 RS Rating

Progyny shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Investors Business Daily

Progyny Clears Key Benchmark, Hitting 80-Plus RS Rating

Progyny Clears Key Benchmark, Hitting 80-Plus RS Rating

Progyny shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 75 to 87.

Investors Business Daily

Progyny Shows Improved Relative Price Performance; Still Shy Of Benchmark

Progyny Shows Improved Relative Price Performance; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Progyny shows improving technical performance. Will it continue?

Investors Business Daily

Stocks Showing Improving Market Leadership: Progyny Earns 81 RS Rating

Stocks Showing Improving Market Leadership: Progyny Earns 81 RS Rating

A Relative Strength Rating upgrade for Progyny shows improving technical performance.

Investors Business Daily

Stocks Showing Rising Market Leadership: Progyny Earns 84 RS Rating

Stocks Showing Rising Market Leadership: Progyny Earns 84 RS Rating

Progyny shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.

Investors Business Daily

Insights into HealthEquity's Upcoming Earnings

HealthEquity (NASDAQ:HQY) is preparing to release its quarterly earnings on Monday, 2024-12-09. Here's a brief overview of what investors should keep in mind before the announcement.

The Latest Analyst Ratings For Progyny

The Latest Analyst Ratings For Progyny

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Progyny (NASDAQ:PGNY) in the last three months.

Get all your
news in one place.

100’s of premium titles.
One news app.

In their rush to offer fertility benefits, employers could be unwittingly creating a new inequity for LGTBQIA+ employees

Most fertility benefits policies exclude same-sex couples who are hoping to build their families (along with single parents by choice).

Employers expand reproductive health benefits amid tight labor market

A growing number of employers are expanding health coverage to in-vitro fertilization, surrogacy and other sometimes pricey fertility services in order to compete in the tight labor market amid heightened awareness of women's health.

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

Looking Into Progyny's Return On Capital Employed

Pulled from Benzinga Pro data, Progyny (NASDAQ:PGNY) showed a loss in earnings since Q3, totaling $15.08 million. Sales, on the other hand, increased by 4.31% to $127.55 million during Q4.

Get all your
news in one place.

100’s of premium titles.
One news app.

Progyny: Q4 Earnings Insights

Progyny (NASDAQ:PGNY) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Progyny beat estimated earnings by 275.0%, reporting an EPS of $0.15 versus an estimate of $0.04.

Progyny's Earnings: A Preview

Progyny (NASDAQ:PGNY) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Progyny will report an earnings per share (EPS) of $0.04.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Investor Business Daily

Electronic Arts

Truist Securities

Canaccord Genuity

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

293,026 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play